TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16224843

Group type: EXPERIMENTAL
Intervention: Intra-operative (Iop) group received 0.5 mg/kg pethidine intravenously at the time of fascia closure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Post-operative (Pop) group received 0.5 mg/kg pethidine intravenously on arrival in the post‐anaesthesia care unit
Number of subjects: 64
Study: 12296888

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inspiratory Resistance-Positive Expiratory Pressure (IR-PEP)
Number of subjects: 70
Study: 11107575

Group type: EXPERIMENTAL
Intervention: Patients with vascular CNS damage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with left hemisphere damage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with good social conditions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group of healthy men aged 18‐24 years
Number of subjects: 90
Study: 7789662

Group type: EXPERIMENTAL
Intervention: Oral sensorimotor therapy for 10 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral sensorimotor therapy for 20 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral sensorimotor therapy (10 and 20 weeks)
Number of subjects: 27
Study: 2299096

Group type: EXPERIMENTAL
Intervention: Maternal antigen avoidance diet (D group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No maternal antigen avoidance diet (ND group)
Number of subjects: 115
Study: 422356

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 30
Study: 31856903

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) plus behavioral experiments (BEs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive therapy (CT) as usual
Number of subjects: 60
Study: 28372320

Group type: EXPERIMENTAL
Intervention: First-rib high-velocity low-amplitude manipulation technique
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham placebo intervention
Number of subjects: 53
Study: 25891115

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (DHA 300 mg/day, EPA 100 mg/day, ARA 120 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (purified olive oil)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 24069148

Group type: EXPERIMENTAL
Intervention: E-mental health approach (online screening and personalized feedback on impaired work functioning and mental health, followed by tailored self-help EMH interventions)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: E-mental health approach
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1140
Study: 21248159

Group type: EXPERIMENTAL
Intervention: Parenteral challenge with MACP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal challenge with MACP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal challenge with MACP (prior MCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal challenge with MACP (prior MACP)
Number of subjects: 0
Study: 18823744

Group type: EXPERIMENTAL
Intervention: Metal-on-metal hip arthroplasty
Number of subjects: 54

Group type: COMPARATOR
Intervention: Metal-on-polyethylene hip arthroplasty
Number of subjects: 54
Study: 17951229

Group type: EXPERIMENTAL
Intervention: Docetaxel plus estramustine (D + E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (M + P)
Number of subjects: 0
Study: 15586629

Group type: EXPERIMENTAL
Intervention: Standard Input Function (SIF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: One-point arterial sampling and SIF
Number of subjects: 10
Study: 11874551

Group type: EXPERIMENTAL
Intervention: 10% Intralipid (2 kcal min(‐1)) - Continuous infusion (CID)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10% Intralipid (2 kcal min(‐1)) - Pulsatile infusion (PID)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 8
Study: 10798029

Group type: EXPERIMENTAL
Intervention: Soap
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ash
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no handwashing agent mentioned)
Number of subjects: 40
Study: 8926741

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (25 mg, cocaine HCl)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (32 mg, cocaine HCl)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Smoked cocaine (42 mg, cocaine base)
Number of subjects: 6
Study: 2181975

Group type: EXPERIMENTAL
Intervention: Polyurethane foam dressings (group 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unna's boot (group 2)
Number of subjects: 36
Study: 7009440

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mcg per inhalationem)
Number of subjects: 6
Study: 30335672

Group type: EXPERIMENTAL
Intervention: Tc nanocolloid
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tc tin colloid
Number of subjects: 27
Study: 30558143

Group type: EXPERIMENTAL
Intervention: Amino acids (BCAA, arginine, citrulline)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27246705

Group type: EXPERIMENTAL
Intervention: Central bundling (zinc and ORS bundled using a pouch with instructional message)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: HC level bundling (zinc, ORS and a similar pouch distributed to the HCs and bundled by health workers)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Bundling without message (zinc, ORS and plain pouch distributed and bundled by health workers)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Status quo (zinc and ORS co-administered without bundling)
Number of subjects: 704
Study: 24673668

Group type: EXPERIMENTAL
Intervention: Ultrasound localization of the puncture site
Number of subjects: 100

Group type: COMPARATOR
Intervention: Palpation of spinal landmarks
Number of subjects: 100
Study: 22818493

Group type: EXPERIMENTAL
Intervention: Standard care plus financial voucher incentives to engage with cessation services
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard care for pregnant smokers
Number of subjects: 600
Study: 20879813

Group type: EXPERIMENTAL
Intervention: New surgical method using a postauricular pedicle periosteal flap and free temporal fascia grafts (Group I)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard operation using only free temporal fascia grafts (Group II)
Number of subjects: 25
Study: 18300441

Group type: EXPERIMENTAL
Intervention: Compound betamethasone injection (1 ml, postaural, single injection)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Merislon and Sibelium (peroral for 2 weeks)
Number of subjects: 27
Study: 15185808

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 20

Group type: COMPARATOR
Intervention: No BIS monitoring
Number of subjects: 20
Study: 12151964

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m2 on day 1 and daily oral UFT 350 mg/m2 in 3 divided doses for 21 days, repeated every 21 days
Number of subjects: 34
Study: 9669186

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 11271190

Group type: EXPERIMENTAL
Intervention: Piggy-back (PB) liver transplantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard technique liver transplantation
Number of subjects: 40
Study: 3290517

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily (suppressive treatment)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Placebo (episodic treatment)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Acyclovir (suppressive therapy)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Acyclovir (episodic therapy)
Number of subjects: 950
Study: 29104118

Group type: EXPERIMENTAL
Intervention: Prasugrel hydrochloride (prasugrel)
Number of subjects: 341
Study: 28027810

Group type: EXPERIMENTAL
Intervention: 1/3 IPV‐Al
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 1/5 IPV‐Al
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 1/10 IPV‐Al
Number of subjects: 240

Group type: COMPARATOR
Intervention: IPV Vaccine SSI
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study: 25588907

Group type: EXPERIMENTAL
Intervention: Enhanced physical activity (additional physical activities such as standing or walking)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care plus (social activities such as card and board games)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Enhanced physical activity
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 198
Study: 24002555

Group type: EXPERIMENTAL
Intervention: CT Q Amplified DNA Assay (CTQ) using SurePath media
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: GC Q Amplified DNA Assay (GCQ) using SurePath media
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: CT Q Amplified DNA Assay (CTQ) using PreservCyt media
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: GC Q Amplified DNA Assay (GCQ) using PreservCyt media
Number of subjects: 4002
Study: 21915543

Group type: EXPERIMENTAL
Intervention: Trochanteric portal (Group B)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Piriformis fossa portal (Group A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 17554786

Group type: EXPERIMENTAL
Intervention: Cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21)
Number of subjects: 40
Study: 16631836

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser pulpotomy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Formocresol pulpotomy
Number of subjects: 137
Study: 15008338

Group type: EXPERIMENTAL
Intervention: Concise White Sealant with air abrasion or air polishing followed by etching
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dyract Seal with air abrasion or air polishing followed by etching
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acid etching (applied to both sealants)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of air abrasion and phosphoric acid etching
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Concise White Sealant
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dyract Seal
Number of subjects: 120
Study: 10764336

Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine (analgesia group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 50
Study: 8962480

Group type: EXPERIMENTAL
Intervention: Implicit learning group with articulatory suppression during both learning and stress trials
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Implicit learning group without articulatory suppression during stress trials
Number of subjects: 32

Group type: COMPARATOR
Intervention: Explicit learning group
Number of subjects: 32
Study: 8354027

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg intravenously)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg chewing gum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of caffeine and nicotine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2941966

Group type: EXPERIMENTAL
Intervention: 5'‐dFUrd 5 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5'‐dFUrd 3 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-risk group (cachectic patients and patients with a pathological EEG before treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EEG monitoring
Number of subjects: 17
Study: 31259807

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (0.125 mg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 220
Study: 29199379

Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach (MIS-TKA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medial parapatellar approach (traditional TKA)
Number of subjects: 50
Study: 27727279

Group type: EXPERIMENTAL
Intervention: A single ultra-low dose of aldesleukin (0.101 × 106 IU/m2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: A single ultra-low dose of aldesleukin (0.497 × 106 IU/m2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lowest doses of aldesleukin (0.040 × 106 and 0.045 × 106 IU/m2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: A single ultra-low dose of aldesleukin
Number of subjects: 40
Study: 25201345

Group type: EXPERIMENTAL
Intervention: Before school physical activity (PA) intervention, 31 minutes per day, 12 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sedentary classroom-based (SC) intervention, 31 minutes per day, 12 weeks
Number of subjects: 202
Study: 22877647

Group type: EXPERIMENTAL
Intervention: Integrative Reactivation and Rehabilitation (IRR) program
Number of subjects: 0
Study: 22129171

Group type: EXPERIMENTAL
Intervention: Dipyridamole 200 mg slow release twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19083719

Group type: EXPERIMENTAL
Intervention: Plyometric program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 16611307

Group type: EXPERIMENTAL
Intervention: ABCM + P (adriamycin, carmustine (BCNU), cyclophosphamide, melphalan with prednisolone)
Number of subjects: 299

Group type: COMPARATOR
Intervention: ABCM (adriamycin, carmustine (BCNU), cyclophosphamide, melphalan)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: ABCM + P
Number of subjects: 299
Study: 12954577

Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg/day
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Arzoxifene 50 mg/day
Number of subjects: 92
Study: 10983645

Group type: EXPERIMENTAL
Intervention: RTV/SQV
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: RTV/SQV/d4T
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: CSF drug concentrations of RTV and SQV
Number of subjects: 208
Study: 9187994

Group type: EXPERIMENTAL
Intervention: Enoximone (EN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dobutamine (DOB) and Nitroglycerin (NTG)
Number of subjects: 20
Study: 8243699

Group type: EXPERIMENTAL
Intervention: Pharmacologic technique (diluted vasopressin 20 U in 20 mL normal saline)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mechanical technique (penrose drain tourniquet and vascular clamps)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 21
Study: 2871294

Group type: EXPERIMENTAL
Intervention: Health Maintenance Organisation (HMO) for high income initially sick individuals
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Health Maintenance Organisation (HMO) for low income initially sick individuals
Number of subjects: 1673

Group type: COMPARATOR
Intervention: Fee-for-service (FFS) care for high income initially sick individuals
Number of subjects: 1673

Group type: COMPARATOR
Intervention: Fee-for-service (FFS) care for low income initially sick individuals
Number of subjects: 1673
Study: 31268383

Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 418
Study: 29426774

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 20 mg/kg/day
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 27416541

Group type: EXPERIMENTAL
Intervention: G5K solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (Ringer's maleate solution)
Number of subjects: 44
Study: 26054178

Group type: EXPERIMENTAL
Intervention: Test group (zinc lactate and magnolia bark extract tablets)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (placebo tablets)
Number of subjects: 100
Study: 22521517

Group type: EXPERIMENTAL
Intervention: Meals on Wheels
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study: 20404425

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.03%
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 17593869

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study: 16491689

Group type: EXPERIMENTAL
Intervention: Variable practice with three different visual distortion lenses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Constant practice with one of several visual distortion lenses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham lenses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Constant practice with visual distortion lenses
Number of subjects: 40
Study: 12441263

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) for 2 years
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 388

Group type: COMPARATOR
Intervention: Control group (observation only)
Number of subjects: 388
Study: 10461302

Group type: EXPERIMENTAL
Intervention: RVS pacing (AAIR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: RVA pacing (VVIR)
Number of subjects: 12
Study: 8603445

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) dose escalation (increased in monthly 25% steps if 75 mg/m2 was tolerated without cytopenias)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional treatment (without dose escalation)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Escalated doses of 6MP (30 children)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional cohort eligible for escalation (37 children)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 6MP dose escalation
Number of subjects: 88
Study: 1577927

Group type: EXPERIMENTAL
Intervention: Intravaginal micronized progesterone (600 mg/day)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Intramuscular progesterone in oil (50 mg/day)
Number of subjects: 262
Study: 6375610

Group type: EXPERIMENTAL
Intervention: Combination of phentermine resin (15 mg in the morning) and fenfluramine hydrochloride (30 mg before the evening meal)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (20 mg three times a day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Phentermine resin (30 mg in the morning)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31083846

Group type: EXPERIMENTAL
Intervention: Group reflection (four sessions based on scenarios related to spiritual care)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lecture on spiritual care (one session)
Number of subjects: 63
Study: 29205601

Group type: EXPERIMENTAL
Intervention: Sodium oxybate treatment
Number of subjects: 336
Study: 26407273

Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (QIV)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Trivalent Influenza Vaccine (TIV)
Number of subjects: 314
Study: 24687003

Group type: EXPERIMENTAL
Intervention: Segmental training
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Prosody training
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combination of segmental and prosody training
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baseline/withdrawal (A)
Number of subjects: 4
Study: 22426247

Group type: COMPARATOR
Intervention: Adaptive design with dose escalation and cohort expansion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive design
Number of subjects: 0
Study: 20716684

Group type: EXPERIMENTAL
Intervention: Bioabsorbable meniscal screws
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bioabsorbable meniscus arrows
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (screws and arrows)
Number of subjects: 42
Study: 18042651

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (5 pmol x kg(‐1) x min(‐1))
Number of subjects: 8
Study: 15610655

Group type: EXPERIMENTAL
Intervention: Modern treatment strategies including chemotherapy and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of chemotherapy doses or cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower-radiation doses and smaller radiation field sizes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More intense drug combinations for high-risk patients
Number of subjects: 0
Study: 11844575

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10782751

Group type: EXPERIMENTAL
Intervention: Daflon 500 (flavonoids diosmin 90% and hesperidin 10%)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7735583

Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone exposure
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study: 2044968

Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.8% MK-417
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CAI treatments (MK-927 and MK-417)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1% MK-417
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1% MK-927
Number of subjects: 20
Study: 7080892

Group type: EXPERIMENTAL
Intervention: Increasing delay training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rapid smoking
Number of subjects: 0
Study: 30754074

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 49
Study: 29756974

Group type: EXPERIMENTAL
Intervention: Core stabilization exercises + lacto-vegetarian diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo + lacto-vegetarian diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 26749217

Group type: EXPERIMENTAL
Intervention: Buprenorphine 3 mg with naltrexone (50 mg initiated 12 hours before and given every 12 hours for 4 doses)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Naltrexone alone (with placebo films)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (placebo films and placebo naltrexone)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Open-label moxifloxacin 400 mg with placebo naltrexone
Number of subjects: 58
Study: 24199667

Group type: EXPERIMENTAL
Intervention: 25 g glucose drink
Number of subjects: 42

Group type: COMPARATOR
Intervention: sweet-tasting placebo drink
Number of subjects: 42